Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide vs Liraglutide in T2D (AWARD-6)
NCT01624259Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2012
- Primary completion
- Nov 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Jun 2012; status: completed.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01624259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01624259.